New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant
stages, such as monoclonal gammaopathy of undetermined significance and smouldering …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely
understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number …

Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which
translates to variable response to treatment and outcome. With the recent increase in …

Based on the clinical features of myeloma and related malignancies of plasma cells, it has
been possible to generate a model system of myeloma progression from a normal plasma …

The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …

Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …

The interpretation of cytogenetic abnormalities in multiple myeloma (MM) is often a
challenging task. MM is characterized by several cytogenetic abnormalities that occur at …